Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Clementia Pharmaceuticals Inc. (NASDAQ: CMTA).

Full DD Report for CMTA

You must become a subscriber to view this report.


Recent News from (NASDAQ: CMTA)

Clementia Pharmaceuticals reports Q3 results
Clementia Pharmaceuticals (NASDAQ: CMTA ): Q3 GAAP EPS of -$0.46. More news on: Clementia Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 07 2018 06:48
Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates
Recent FDA Meeting Identifies Path Towards NDA Submission in the Second Half of 2019 Financing Raises $75 million to Support a Potential Commercial Launch MONTREAL, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical...
Source: GlobeNewswire
Date: November, 07 2018 06:30
Clementia prices equity offering
Clementia Pharmaceuticals Inc. (NASDAQ: CMTA ) has priced public offering of 5.3M common shares at $13.25 per share, for estimated gross proceeds of $70.2M. More news on: Clementia Pharmaceuticals, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: October, 30 2018 05:23
Clementia Announces Pricing of Public Offering of Common Shares
MONTREAL, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the pricing of an underwritten public offering of 5,3...
Source: GlobeNewswire
Date: October, 29 2018 21:21
Clementia Announces Proposed Public Offering of Common Shares
MONTREAL, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that it intends to offer and sell, subject to market ...
Source: GlobeNewswire
Date: October, 29 2018 16:01
Consolidated Research: 2018 Summary Expectations for Insys Therapeutics, Achaogen, Astec Industries, Central European Media Enterprises, Pzena Investment Management, and Clementia Pharmaceuticals - Fundamental Analysis, Key Performance Indications
NEW YORK, Oct. 29, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Insys Therapeutics, Inc. (NASDAQ:INSY), Achaogen, Inc. (NASDAQ:AKAO), ...
Source: GlobeNewswire
Date: October, 29 2018 08:55
Innovative Advancements in Brain Tumor Therapies Holding Promise for Revolutionary Treatments
October 25, 2018 Palm Beach, FL – (October 25, 2018) – Cancer has a major impact on the health and well being of individuals across the globe. Cancer is identified as one of the leading causes of death worldwide. In 2017, approximately 0.5% of the world’s population ...
Source: Financial News Media
Date: October, 25 2018 08:17
Midday Gainers / Losers (09/07/2018)
Gainers:  OKTA +20% . NVUS +17% . XENE +16% . NX +16% . DRNA +15% . ZEAL +15% . SHLO +15% . TIS +13% . FIVE +13% . MCFT +11% . More news on: Okta, Inc., Novus Therapeutics, Xenon Pharmaceuticals, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 07 2018 12:47
Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences
MONTREAL, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the company’s participation at the followin...
Source: GlobeNewswire
Date: September, 05 2018 06:30
Consolidated Research: 2018 Summary Expectations for GSV Capital, NantHealth, Gold Fields, Sogou Inc. Sponsored ADR, Clementia Pharmaceuticals, and Arbutus Biopharma - Fundamental Analysis, Key Performance Indications
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of GSV Capital Corp (NASDAQ:GSVC), NantHealth, Inc. (NASDAQ:NH), Gold Fields...
Source: GlobeNewswire
Date: August, 21 2018 07:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0812.3810.2412.416810.1514142,757
2018-05-1717.5818.2518.787417.5812,505

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-102,83124,55311.5302Cover
2018-12-075,50111,13249.4161Short
2018-12-065,4509,33058.4137Short
2018-12-047,32939,21418.6898Cover
2018-12-034,62910,06445.9956Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CMTA.


About Clementia Pharmaceuticals Inc. (NASDAQ: CMTA)

Logo for Clementia Pharmaceuticals Inc. (NASDAQ: CMTA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CMTA)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 09 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 20 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 23 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 06 2018
      Annual and transition report of foreign private issuers under sections 13 or 15(d)
      Filing Type: 20-FFiling Source: edgar
      Filing Date: February, 28 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: February, 28 2018

       

       


      Daily Technical Chart for (NASDAQ: CMTA)

      Daily Technical Chart for (NASDAQ: CMTA)


      Stay tuned for daily updates and more on (NASDAQ: CMTA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CMTA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CMTA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CMTA and does not buy, sell, or trade any shares of CMTA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/